| Jul 30 |
Heron Therapeutics to Report Second Quarter 2024 Financial Results On Tuesday, August 6, 2024
|
| Jul 25 |
While shareholders of Heron Therapeutics (NASDAQ:HRTX) are in the black over 1 year, those who bought a week ago aren't so fortunate
|
| Jul 15 |
Heron Therapeutics Announces the Inclusion of ZYNRELEF® as a Qualifying Product Under the Proposed 2025 Non-Opioid Policy for Pain Relief Under the OPPS and the ASC Payment System
|
| Jul 11 |
Heron Therapeutics (HRTX) Upgraded to Strong Buy: Here's What You Should Know
|
| Jul 10 |
Indivior (INDV) Down on Dropping Schizophrenia Drug, Cuts '24 View
|
| Jul 2 |
Heron Therapeutics announces acceptance of PAS application for dual-acting anesthetic
|
| Jul 2 |
Merck (MRK) Gets Exclusive Rights to Opevesostat From Partner
|
| Jul 2 |
Heron Therapeutics Announces Acceptance of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN")
|
| Jun 30 |
With 55% ownership of the shares, Heron Therapeutics, Inc. (NASDAQ:HRTX) is heavily dominated by institutional owners
|
| Jun 27 |
Heron Therapeutics: Opioid-Free Surgical Pain Relief Maven With Low Cash Reserves
|
